List of Excipients in Branded Drug DILTIAZEM HYDROCHLORIDE IN SODIUM CHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
WG Critical Care LLC	DILTIAZEM HYDROCHLORIDE IN SODIUM CHLORIDE	diltiazem hydrochloride	44567-662	CITRIC ACID MONOHYDRATE
WG Critical Care LLC	DILTIAZEM HYDROCHLORIDE IN SODIUM CHLORIDE	diltiazem hydrochloride	44567-662	HYDROCHLORIC ACID
WG Critical Care LLC	DILTIAZEM HYDROCHLORIDE IN SODIUM CHLORIDE	diltiazem hydrochloride	44567-662	SODIUM CHLORIDE
WG Critical Care LLC	DILTIAZEM HYDROCHLORIDE IN SODIUM CHLORIDE	diltiazem hydrochloride	44567-662	SODIUM HYDROXIDE
WG Critical Care LLC	DILTIAZEM HYDROCHLORIDE IN SODIUM CHLORIDE	diltiazem hydrochloride	44567-662	SORBITOL

Diltiazem Hydrochloride in Sodium Chloride: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 27, 2026

Diltiazem hydrochloride in sodium chloride is a mature injectable cardiovascular product with limited active-ingredient patent risk and stronger commercial differentiation potential in manufacturing, packaging, stability, supply reliability and ready-to-administer hospital formats. The core formulation is relatively simple: diltiazem hydrochloride in an aqueous sodium chloride vehicle, generally adjusted to physiologic tonicity and packaged for intravenous administration. Value creation is more likely to come from premixed delivery, container-closure systems, preservative-free manufacturing and hospital workflow advantages than from a novel excipient platform.

What is diltiazem hydrochloride in sodium chloride used for?

Diltiazem hydrochloride injection is an intravenous calcium-channel blocker used primarily for:

• Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter.
• Conversion and prevention of paroxysmal supraventricular tachycardia.
• Short-term rate control when oral therapy is not practical.

The product is administered by intravenous bolus, followed in some cases by continuous infusion. FDA labeling identifies diltiazem hydrochloride injection as a sterile, nonpyrogenic solution for intravenous use. The product is generally supplied in single-dose vials or pharmacy-prepared infusion formats, while ready-to-use presentations may use sodium chloride injection as the diluent.[1]

Diltiazem is not a biologic. Biosimilar regulation does not apply. Competitive entry occurs through abbreviated new drug applications, 505(b)(2) applications, hospital compounding, outsourcing-facility products and institutional purchasing contracts.

What excipients are used in diltiazem hydrochloride sodium chloride injection?

The principal excipients are sodium chloride and water for injection. Some products may include pH-adjusting agents, depending on the formulation and manufacturer. The exact inactive-ingredient profile must be confirmed against the applicable FDA label and product presentation.

Component	Functional role	Commercial relevance
Diltiazem hydrochloride	Active pharmaceutical ingredient	Controls potency, dose uniformity and solution stability
Sodium chloride	Tonicity agent and vehicle component	Supports intravenous tolerability and simplifies formulation
Water for injection	Solvent	Must meet parenteral quality requirements
Hydrochloric acid or sodium hydroxide, where used	pH adjustment	Controls solubility, stability and compatibility
Container-closure system	Product protection and delivery	Affects adsorption, extractables, leachables and shelf life

A sodium chloride formulation has a limited excipient burden. That reduces formulation complexity and can simplify regulatory review. It also limits differentiation based on excipient novelty. The principal technical risks are pH control, degradation, particulate formation, container compatibility, microbial control and dilution compatibility.

How should the excipient strategy be designed?

The strongest strategy is a minimal-excipient, preservative-free formulation optimized for hospital administration.

Tonicity and sodium chloride concentration

Sodium chloride provides a familiar parenteral vehicle and helps reduce the risk of local irritation associated with markedly hypotonic or hypertonic solutions. A formulation based on 0.9% sodium chloride has operational advantages because hospitals already stock and administer normal saline.

The formulation should avoid unnecessary ionic species. Additional buffers, antioxidants or surfactants may create new compatibility and regulatory burdens without offering a meaningful clinical benefit. A simple composition also supports manufacturing scale-up and reduces the number of critical quality attributes.

pH control

Diltiazem hydrochloride is a salt-form active ingredient with aqueous solubility suitable for injectable use. pH remains a central development parameter because it can affect:

• Chemical degradation.
• Solubility and precipitation risk.
• Container interaction.
• Infusion-site tolerability.
• Compatibility after dilution.
• Stability under refrigerated and room-temperature conditions.

A controlled pH range should be established through forced-degradation studies, accelerated stability, photostability, in-use stability and dilution studies. The target should be based on the product's demonstrated stability rather than on unnecessary imitation of a reference product.

Preservative-free positioning

Preservative-free presentation is commercially preferable for intravenous cardiovascular use. It supports single-dose administration, reduces concern about preservative exposure and aligns with hospital expectations for sterile injectable products.

Multidose presentations may reduce packaging cost but create additional antimicrobial-preservation, labeling and in-use stability requirements. They also face a weaker clinical and procurement proposition in acute-care settings.

Container-closure selection

The container system may create more defensible product value than the excipient composition. Relevant options include:

• Glass vials.
• Polymer vials.
• Flexible infusion bags.
• Ready-to-administer syringes.
• Dual-chamber or proprietary transfer systems.

Critical studies should evaluate adsorption of diltiazem to polymer surfaces, extractables and leachables, stopper compatibility, oxygen and moisture transmission, particulate generation and closure integrity.

A flexible bag can improve pharmacy efficiency but requires careful assessment of diltiazem stability in the bag film and at the administration port. A prefilled syringe can reduce preparation steps but carries higher device, human-factors and combination-product requirements.

What formulations are protected by patents?

The basic diltiazem hydrochloride in sodium chloride formulation is unlikely to have a strong, enforceable composition-of-matter patent position because:

1. Diltiazem hydrochloride is an established active ingredient.
2. Sodium chloride injection is a conventional parenteral vehicle.
3. Intravenous diltiazem products have been marketed for decades.
4. A simple aqueous solution generally offers limited room for broad, non-obvious formulation claims.

Potentially relevant patent categories include:

• Specific concentration ranges.
• Defined pH windows.
• Stability-enhancing excipient combinations.
• Ready-to-use infusion bags.
• Premixed bolus or infusion products.
• Container-closure systems.
• Low-sorbitol or preservative-free compositions.
• Manufacturing processes that reduce impurities.
• Extended room-temperature stability.
• Compatibility with automated infusion devices.

These claims would need to demonstrate a measurable technical advantage. A patent directed only to diltiazem hydrochloride dissolved in sodium chloride would face substantial prior-art and obviousness exposure.

What is the Orange Book status of diltiazem injection?

Diltiazem hydrochloride injection products are generally regulated as conventional small-molecule drug products. Relevant listings may include reference products and approved generic products, depending on the specific strength, dosage form and manufacturer.

The Orange Book should be reviewed by exact product presentation because injectable diltiazem products can differ by:

• Concentration.
• Single-dose vial versus premixed bag.
• Route and method of administration.
• Reference listed drug designation.
• Listed patents and regulatory exclusivities.

There is no biosimilar pathway for this product. A generic applicant typically relies on an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable injectable-product requirements. A 505(b)(2) pathway may be relevant where the proposed product differs materially in formulation, presentation, dosing device or labeling.

When does diltiazem injection lose exclusivity?

The key exclusivity periods for the active ingredient have expired. Diltiazem was approved and commercialized decades ago, and the market has long included generic injectable products. Any current commercial protection is therefore more likely to derive from product-specific patents, regulatory exclusivity, manufacturing complexity, supply arrangements or institutional contracting than from basic active-ingredient exclusivity.

Exclusivity category	Current commercial assessment
Active-ingredient patent	Expired
Basic formulation protection	Limited or likely expired for legacy products
Biosimilar exclusivity	Not applicable
New drug exclusivity	Expired for legacy diltiazem injection products
Device or presentation patents	Possible for newer ready-to-use formats
Manufacturing trade secrets	Potentially important
Contractual hospital supply position	Commercially relevant but not statutory exclusivity

A new premixed diltiazem presentation could obtain limited regulatory protection if it qualifies as a new drug product with a novel formulation or delivery system. That protection would not restore exclusivity over diltiazem itself.

Are there Paragraph IV challenges involving diltiazem hydrochloride injection?

Paragraph IV risk is generally low for the legacy product because generic diltiazem injection has already entered the market. Paragraph IV litigation would be more relevant to a newly patented presentation, such as:

• A ready-to-administer bag.
• A prefilled syringe.
• A novel stable concentration.
• A proprietary container system.
• A formulation with extended room-temperature storage.

For a new product-specific patent, an ANDA applicant could challenge listed patents through a Paragraph IV certification. The commercial impact would depend on whether the patent claims cover the product as sold or only a narrow formulation feature.

No current litigation or settlement terms should be assumed without a product-specific search of FDA Orange Book listings, federal court dockets and the applicable manufacturer’s patent portfolio.

How strong is the patent estate for diltiazem hydrochloride in sodium chloride?

The patent estate is weak for the basic formulation and potentially moderate for differentiated delivery formats.

Patent layer	Expected strength	Reason
Diltiazem molecule	Very low	Legacy active ingredient
Diltiazem hydrochloride salt	Very low	Established pharmaceutical form
Sodium chloride vehicle	Very low	Conventional parenteral excipient
Basic aqueous injection	Low	Broad prior art and long commercial history
Narrow stability composition	Low to moderate	Depends on unexpected stability data
Premixed infusion bag	Moderate	May protect a defined combination of formulation and packaging
Prefilled syringe or delivery device	Moderate	Device and human-factors claims may add protection
Manufacturing impurity-control process	Moderate	Can be valuable if difficult to replicate
Supply-chain and quality systems	Commercially strong but not patent-based	May deter entry without creating legal exclusivity

The most defensible intellectual property would likely combine formulation claims with packaging, stability and use limitations. A single broad claim covering diltiazem hydrochloride in sodium chloride would be vulnerable.

What commercial opportunities exist for excipient and presentation innovation?

Ready-to-administer hospital products

The largest opportunity is operational. Emergency departments, intensive-care units and cardiac units use intravenous rate-control products under time pressure. A ready-to-administer bag or syringe can reduce:

• Pharmacy compounding time.
• Dose-calculation errors.
• Manipulation of sterile containers.
• Waste from partially used vials.
• Delays in treatment.
• Exposure to drug shortages.

A product can be differentiated through validated concentrations, standardized dosing instructions and compatibility with commonly used infusion pumps.

Premixed infusion bags

Premixed bags are attractive because sodium chloride is already familiar to hospital pharmacies. The commercial proposition improves if the product offers:

• Long room-temperature storage.
• Reduced overwrap requirements.
• Multiple bag sizes.
• Clear labeling for bolus versus infusion use.
• Low residual volume.
• Compatibility with common administration sets.

The formulation must demonstrate stability during shipping, storage and administration. Bag-film compatibility is a central development issue.

Prefilled syringes

A prefilled syringe could target emergency departments and procedural settings where rapid bolus dosing is required. Its advantages include dose standardization and reduced preparation. Its disadvantages are higher manufacturing cost, device qualification, particulate control and greater regulatory complexity.

Outsourcing-facility supply

Hospitals may source compounded diltiazem infusions from 503B outsourcing facilities during shortages or when pharmacy labor is constrained. A manufacturer with robust sterile capacity could compete through reliable national distribution, batch release speed and validated beyond-use dating.

Global markets

The strongest geographic opportunity is in markets with:

• High generic penetration.
• Hospital procurement based on supply reliability.
• Frequent sterile-injectable shortages.
• Limited availability of premixed cardiovascular products.
• Growing use of emergency-care protocols.

Regulatory requirements differ across the United States, European Union, Canada, Japan and emerging markets. A formulation designed for multiple jurisdictions should minimize excipients, use widely accepted parenteral materials and support a common stability package.

How does diltiazem compare with competing intravenous rate-control products?

Product	Active ingredient	Main competitive position
Diltiazem injection	Diltiazem hydrochloride	Effective rate control; commonly used in atrial fibrillation with rapid ventricular response
Metoprolol injection	Metoprolol tartrate	Alternative beta-blocker with different hemodynamic and contraindication profile
Esmolol injection	Esmolol hydrochloride	Short-acting beta-blocker; premium positioning may reflect titratability
Verapamil injection	Verapamil hydrochloride	Alternative calcium-channel blocker with narrower practical use in some settings
Amiodarone injection	Amiodarone hydrochloride	Used in selected arrhythmia settings; different toxicity and administration profile

Diltiazem competes on familiarity, rate-control efficacy and generic cost. A differentiated product must improve administration economics rather than rely on active-ingredient novelty.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are more important than formulation novelty. Sterile injectable production requires:

• Validated aseptic processing.
• Endotoxin and sterility control.
• Particulate testing.
• Container-closure integrity testing.
• Robust visual inspection.
• Precise fill-volume control.
• Reliable API sourcing.
• Stability data for the marketed container system.

Supply risk can arise from a limited number of qualified diltiazem API suppliers, sterile-fill capacity constraints, glass or polymer component shortages and hospital contract concentration.

Trade secrets may protect impurity profiles, sterilization controls, filling parameters and packaging know-how. These protections can support commercial advantage but do not prevent a technically capable competitor from developing an equivalent product.

What generic launch risks exist?

A new entrant faces low legal barriers but meaningful execution risks:

1. Failure to demonstrate adequate stability in the chosen container.
2. Precipitation after dilution or co-administration.
3. Particulate or leachable findings.
4. Inability to secure reliable sterile manufacturing capacity.
5. Price compression from established generic suppliers.
6. Hospital reluctance to convert from familiar vial products.
7. Limited purchasing volume outside shortage periods.
8. Inadequate differentiation to justify a premium.

The strongest launch scenario is a supply-secure, ready-to-use product sold through hospital group purchasing organizations and direct institutional contracts. A conventional vial with no price or supply advantage would face limited commercial upside.

Key Takeaways

• Diltiazem hydrochloride in sodium chloride is a mature sterile injectable product with expired active-ingredient exclusivity.
• The core excipient strategy should remain simple, preservative-free and compatible with intravenous administration.
• Sodium chloride offers operational familiarity but little patent differentiation.
• Container systems, premixed bags, prefilled syringes and extended stability are the main commercial innovation areas.
• Patent strength is weak for the basic solution and stronger only for narrow formulation, packaging or device claims.
• Biosimilar risk does not apply because diltiazem is a small-molecule drug.
• Paragraph IV risk is relevant mainly to newly patented ready-to-use presentations.
• Manufacturing reliability, sterile capacity and hospital procurement access are more important than broad formulation patents.
• The most attractive opportunity is a ready-to-administer product that reduces pharmacy preparation and addresses injectable supply constraints.

FAQs

Can diltiazem hydrochloride injection use sodium chloride 0.9% as a diluent?

Yes. Sodium chloride injection is a standard parenteral vehicle used for diltiazem administration and dilution, subject to the applicable product label and compatibility instructions.[1]

Is a diltiazem sodium chloride formulation eligible for a new patent?

Possibly, but a patent would need to claim a non-obvious technical feature, such as improved stability, a defined container system, an unusual concentration or a manufacturing process that produces a measurable benefit.

Does diltiazem injection require a preservative?

A preservative-free formulation is generally preferable for intravenous hospital use. The final requirement depends on the presentation, container system, dosing instructions and regulatory strategy.

Can a 503B outsourcing facility sell diltiazem in sodium chloride?

A qualifying 503B outsourcing facility may compound and distribute eligible sterile products under the Federal Food, Drug, and Cosmetic Act framework. The facility must meet applicable outsourcing-facility, quality, labeling and reporting requirements.[2]

What is the best commercial format for a new diltiazem injectable product?

A ready-to-administer premixed bag or prefilled syringe is more differentiated than a conventional vial. The strongest product would combine validated stability, low preparation burden, broad hospital compatibility and reliable supply.

References

1. U.S. Food and Drug Administration. (2024). Diltiazem hydrochloride injection prescribing information. DailyMed, National Library of Medicine.

2. U.S. Food and Drug Administration. (2023). Outsourcing facility registration and product reporting. https://www.fda.gov/drugs/human-drug-compounding/outsourcing-facility-registration-and-product-reporting

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. United States Pharmacopeia. (2024). General chapter <797>: Pharmaceutical compounding - sterile preparations. U.S. Pharmacopeial Convention.